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Office-based balloon sinus dilation (BSD) is becoming an increasingly popular modality to treat chronic rhinosinusitis (CRS) that is refractory to conventional medical management. A previous paper by the authors demonstrated statistically significant improvements in patients' quality of life in the shortterm (24 weeks) following BSD. The authors thus attempted to evaluate patientreported outcomes one year after office-based BSD by measuring changes in average sinonasal outcome test (SNOT-20) scores.
Sikand et al developed a prospective, single-arm, multicenter study for officebased BSD in patients eighteen years and older diagnosed with CRS. All patients had previously failed medical management. Patients with severe nasal polyposis were excluded due to limited access to necessary anatomic locations. Patients underwent in-office BDS under local anesthesia for diseased frontal, maxillary, and sphenoid sinuses. SNOT-20 scores were compared preand postoperatively; improvement in sinus symptoms was measured by the mean change. SNOT-20 subscores were also analyzed, evaluating which aspects of quality of life (QOL) were most affected by BSD. Patients were re-examined at one-year follow-up to evaluate changes in SNOT-20 scores and revision surgery.
Across thirteen centers, 197 patients were invited to participate in the study, of which 122 (62%) patients enrolled in and completed one-year follow-up. The average follow up was 1.4 years. 58 of 122 (47.5%) had previous sinus surgery. The average preoperative SNOT-20 score was 2.1 and one-year follow-up score was 1.0 for a mean reduction of -1.1. All twenty subscores from the SNOT-20 demonstrated a statistically significant mean change from baseline at the oneyear follow-up, with the largest improvement in average score seen in facial pain and pressure, waking up tired, and fatigue. Sixty-one of 102 patients (60%) demonstrated ethmoid Lund-Mackay scores greater than zero, with an average of 2.8 (out of 8), indicating a radiographic presence of ethmoid disease. These patients experienced a reduction in SNOT-20 score (pre ϭ 2.1, post ϭ 1.0) comparable to reductions seen in patients without ethmoid involvement (pre ϭ 2.0, post ϭ 1.2) at one-year follow-up. Overall, nine patients required revision procedures due to recurrence of symptoms; two were treated with office-based BSD, while seven required sinus surgery in the operating room. Eight of these revision patients had ethmoid involvement; however, there were no statistically significant baseline characteristics predictive for revision procedures.
The major strength of this study is that it adds to the growing body of research demonstrating office-based BSD is an effective, minimally invasive procedure for patients with CRS. The study design prospectively enrolled patients at multiple centers across the country, showing improved QOL through a minimum of 52 weeks. This suggests that the inherent challenge of the office-based procedures does not limit QOL as long as the patient is appropriately selected for BSD. A weakness of the study is the lack of medical standardization preoperatively and postoperatively in patients with CRS. Further, only 122 of the original 203 patients enrolled in one-year follow-up, though not all of the original patients chose to re-enroll and instead completed the follow-up protocol to which they agreed. Lastly, there was no mention of adverse events, if any.
Overall, this is an excellent study that contributes to the expanding evidence for office-based BSD. This study highlights the effectiveness in sustaining significant improvement in quality of life at one year postprocedure for appropriately selected patients with chronic rhinosinusitis. 
